Carcinoma, Renal Cell: all 1,992 studies
Page 16 of 20. Open to participants first (387), then studies with results posted, then the rest; newest registration first within each.
- A Multicenter Phase I Study of MRX34, MicroRNA miR-RX34 Liposomal InjectionTerminatedNCT01829971Phase 1
- A Study of Famitinib in Patients With Advanced Metastatic Renal Cell CancerCompletedNCT01829841Phase 2
- Autologous Dendritic Cells in Treating Patients With Metastatic Kidney CancerCompletedNCT01826877Phase 1
- A Phase II Study of Axitinib in Metastatic Non-clear Cell Renal Cell Carcinoma Patients Previously Treated With TemsirolimusCompletedNCT01798446Phase 2
- A Study Comparing AZD2014 vs Everolimus in Patients With Metastatic Renal CancerTerminatedNCT01793636Phase 2
- 1st-line Activity of Dovitinib and Correlation With Genetic Changes in RCCStatus unknownNCT01791387Phase 2
- Efficacy Study of Sunitinib and Everolimus (Rotational vs Sequential Arm) in Pats. With m Clear Cell Renal CancerTerminatedNCT01784978Phase 2
- A Post Marketing Surveillance As Required By Philippine Food And Drug AdministrationWithdrawnNCT01781442
- Intraoperative Imagery of Renal Nodules With Folate-fluorescein Conjugate(EC17)CompletedNCT01778933Early Phase 1
- Clinical and Histopathologic Characteristics of BAP1 MutationsCompletedNCT01773655
- Remote Ischemia Pre-Conditioning in Patients Undergoing Partial NephrectomyTerminatedNCT01771003Not applicable
- Tivozanib Before Surgery in Treating Patients With Localized Kidney CancerWithdrawnNCT01769885Not applicable
- REDECT 2: REnal Masses: Pivotal Trial to DEteCT Clear Cell Renal Cell Carcinoma With PET/CTWithdrawnNCT01762592Phase 3
- Sorafenib Combined With Chemotherapy for Renal Collecting Duct CarcinomaCompletedNCT01762150Phase 2
- A Phase 2 Study of ASONEP™ to Treat Unresectable and Refractory Renal Cell CarcinomaTerminatedNCT01762033Phase 2
- Open-label Pilot Evaluating Renal Lesions w/ Contrast-enhaced US in Patients w/ Renal CancerCompletedNCT01751529Early Phase 1
- Sequential Therapy in Metastatic Renal Cell CarinomaCompletedNCT01731158Phase 2
- Sorafenib in Elderly mRCCCompletedNCT01728948
- Recombinant Interleukin-15 in Treating Patients With Advanced Melanoma, Kidney Cancer, Non-small Cell Lung Cancer, or Squamous Cell Head and Neck CancerCompletedNCT01727076Phase 1
- Novel Controlled Hypo-Perfusion Technique in Partial NephrectomyTerminatedNCT01720693Phase 2
- Biomarkers Before and After Nephrectomy of Locally Advanced or Metastatic Renal Cell Carcinoma Treated With EverolimusCompletedNCT01715935Phase 2
- Dose Escalation Study Investigating Everolimus and Dovitinib in Metastatic Clear Cell Renal CancerCompletedNCT01714765Phase 1
- Sunitinib Drug Levels and Outcomes in Kidney CancerStatus unknownNCT01711268
- Study Using FolateScan to Identify Subjects With Folate Receptor-Positive Metastatic Renal Cell CarcinomaCompletedNCT01689766Phase 2
- Safety and Efficacy of FolateScan (Technetium Tc 99m EC20) in Subjects With Suspected Metastatic Renal Cell CarcinomaCompletedNCT01689662Phase 2
- Pazopanib Hydrochloride and Bevacizumab in Treating Patients With Previously Untreated Metastatic Kidney CancerActive, not recruitingNCT01684397Phase 1/2
- A Phase 1b Study of SGN-75 in Combination With Everolimus in Patients With Renal Cell CarcinomaTerminatedNCT01677390Phase 1
- A Pilot Study of Focal Ablative STereotactic RAdiosurgery for Cancers of the Kidney or Isolated Adrenal MetastasesCompletedNCT01676428Not applicable
- A Study to Assess the Safety, Pharmacokinetics and Effectiveness of AGS-16C3F Monotherapy in Subjects With Renal Cell Carcinoma (RCC) of Clear Cell or Papillary HistologyCompletedNCT01672775Phase 1
- PET Quantitative Assessments of Solid Tumor Response to Immune Checkpoint Blockade TherapyCompletedNCT01666353Early Phase 1
- Imaging Correlates of Renal Cell Carcinoma Biological FeaturesCompletedNCT01665703Not applicable
- Observational Study of Real World Effectiveness Data and Safety in Patients Receiving Pazopanib With Advanced or Metastatic Renal Cell CarcinomaCompletedNCT01649778
- Studying Biomarkers in Samples From Younger Patients With Kidney CancerWithdrawnNCT01642095
- Romidepsin in Treating Patients With Lymphoma, Chronic Lymphocytic Leukemia, or Solid Tumors With Liver DysfunctionCompletedNCT01638533Phase 1
- CRLX101 Plus Bevacizumab in Advanced RCCCompletedNCT01625936Phase 1
- A Study of CD45RA+ Depleted Haploidentical Stem Cell Transplantation in Children With Relapsed or Refractory Solid Tumors and LymphomasCompletedNCT01625351Phase 1
- Everolimus/Sorafenib or Sunitinib in Patients With Metastatic Renal Cell Carcinoma (RCC)WithdrawnNCT01616186Phase 2
- Phase III Sequential Open-label Study to Evaluate the Efficacy and Safety of Sorafenib Followed by Pazopanib Versus Pazopanib Followed by Sorafenib in the Treatment of Advanced / Metastatic Renal Cell Carcinoma (SWITCH-II)CompletedNCT01613846Phase 3
- A Feasibility Study for a Multicentre Randomised Controlled Trial to Compare Surgery With Needle Ablation Techniques in People With Small Renal Masses (4cm)CompletedNCT01608165Not applicable
- An Observational Pilot Study Evaluating the Feasibility of Conducting Genome-Wide Association Studies Utilizing Subject Provided Information in Subjects With Locally Recurrent or MBC, MCRC, MNSCLC, RGBM or MRCC Treated With Avastin (Bevacizumab) (InVite)CompletedNCT01598597
- Relation Between Safety Endpoints and Everolimus Trough Blood Level in Advanced Renal Cell CarcinomaTerminatedNCT01598038Not applicable
- Aerosolized Aldesleukin in Treating Patients With Lung MetastasesActive, not recruitingNCT01590069Phase 1/2
- Duration of Treatment With Tyrosine Kinase Inhibitors in the Treatment of Metastatic Renal Cell CarcinomaCompletedNCT01585974
- Phase 3 Trial of Autologous Dendritic Cell Immunotherapy Plus Standard Treatment of Advanced Renal Cell CarcinomaTerminatedNCT01582672Phase 3
- Pazopanib in Second-line Therapy in Renal Cell CarcinomaStatus unknownNCT01577784Phase 2
- Vascular Targeted Photodynamic Therapy T1a Renal TumoursTerminatedNCT01573156Phase 1/2
- Trying Activity in Kidney Cancer Survivors (TRACKS) TrialCompletedNCT01571401Phase 2
- Second-line Pazopanib Renal Cell Carcinoma (RCC) Study. CTRIAL-IE (ICORG) 10-01, V5CompletedNCT01566747Phase 2
- Nexavar Dosing in Renal Cancer Patients in "Real-life" SettingCompletedNCT01557127
- Trebananib And Temsirolimus in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by SurgeryCompletedNCT01548482Phase 1
- Clamped or Unclamped Surgery in Treating Patients With Kidney CancerTerminatedNCT01547676Not applicable
- Urine Proteome of Surgical Patients and Healthy VolunteersCompletedNCT01538823
- pazopanib_NCRCC,Ph2 STUDYCompletedNCT01538238Phase 2
- A Clinical Study to Evaluate Safety and Immunologic Response of COMBIG-DC, in Patients With Metastatic Kidney CancerCompletedNCT01525017Phase 1
- CREATE: Cross-tumoral Phase 2 With CrizotinibCompletedNCT01524926Phase 2
- Vaccine Therapy With or Without Sirolimus in Treating Patients With NY-ESO-1 Expressing Solid TumorsCompletedNCT01522820Phase 1
- First Line Pazopanib in Poor Risk Patients With Metastatic Renal Cell CarcinomaCompletedNCT01521715Phase 4
- Pazopanib in Combination With Interferon Alfa 2-A, in Patients With Advanced Renal Cell CarcinomaCompletedNCT01513187Phase 1/2
- A Phase II Study Investigating Upfront Pazopanib In Metastatic Renal Cancer Renal Cancer (Panther)Status unknownNCT01512186
- Autophagy Inhibition to Augment Mammilian Target of Rapamycin (mTOR) Inhibition: A Phase I/II Trial of RAD001 and Hydroxychloroquine (HCQ) in Patients With Previously Treated Renal Cell CarcinomaCompletedNCT01510119Phase 1/2
- Nexavar as First Targeted Therapy in Patients With Advanced Renal Cell CarcinomaCompletedNCT01508364
- Profile of Soluble and Cellular Biomarkers and of Functional Imaging During Antiangiogenic Therapies in Cancer PatientsTerminatedNCT01507740
- Study of Efficacy and Safety of Sunitinib Given on an Individualized ScheduleCompletedNCT01499121Phase 2
- AMG 172 First in Human Study in Patients With Kidney CancerCompletedNCT01497821Phase 1
- Sorafenib Tosylate and Hypoxia-Activated Prodrug TH-302 in Treating Patients With Advanced Kidney Cancer or Liver Cancer That Cannot Be Removed By SurgeryCompletedNCT01497444Phase 1
- RGD-PET-CT in Cancer AngiogenesisTerminatedNCT01492192Phase 2
- A Rollover Protocol for Subjects Previously Treated With AGS-003TerminatedNCT01482949Phase 2
- Genome-wide Association Study to Predict Treatment Response for Molecular Targeted Therapy in Hepatocellular Carcinoma and Renal Cell CarcinomaCompletedNCT01482520
- Dose Finding Study of RAD001 (Everolimus, Afinitor®) in Combination With BEZ235 in Patients With Advanced Solid TumorsCompletedNCT01482156Phase 1
- Comparison of Sequential Therapies With Sunitinib and Sorafenib in Advanced Renal Cell CarcinomaStatus unknownNCT01481870Phase 3
- Akt Inhibitor MK2206 and Hydroxychloroquine in Treating Patients With Advanced Solid Tumors, Melanoma, Prostate or Kidney CancerActive, not recruitingNCT01480154Phase 1
- Clinical Study With Axitinib In Advanced Kidney Cancer, Who Have Failed First Line TreatmentNo longer availableNCT01473043
- Effect of Sorafenib or Regorafenib on P63 Expression and Keratinocyte Differentiation in Human SkinTerminatedNCT01466504
- Study of Everolimus and Low-dose Cyclophosphamide in Patients With Metastatic Renal Cell CancerCompletedNCT01462214Phase 1/2
- Hepatic Monitoring for PazopanibCompletedNCT01449825
- The Molecular Predisposition to Hereditary Nonpolyposis Colon Cancer (HNPCC)Status unknownNCT01447199
- Cardiovascular and Torsades de Pointes Monitoring for PazopanibCompletedNCT01446224
- Evaluate the Efficacy of Sorafenib in Renal Cell Carcinoma Patients After a Radical Resection of the MetastasesStatus unknownNCT01444807Phase 2
- Study of GDC-0980 Versus Everolimus in Participants With Metastatic Renal Cell Carcinoma Who Have Progressed on or Following Vascular Endothelial Growth Factor- (VEGF) Targeted TherapyCompletedNCT01442090Phase 2
- Sunitinib Intake Conditions in the Treatment of Patients With Renal Cell CarcinomaCompletedNCT01441661
- A Study Of Crizotinib Plus VEGF Inhibitor Combinations In Patients With Advanced Solid Tumors.WithdrawnNCT01441388Phase 1
- PROCLAIM Registry to Evaluate the Treatment Patterns and Clinical Response in MalignancyCompletedNCT01415167
- Nexavar Post-marketing Surveillance for RCC in Japan: Early Access ProgramCompletedNCT01412671
- Nexavar Post-marketing Surveillance for Renal Cell Carcinoma in JapanCompletedNCT01411423
- Rotating Pazopanib and Everolimus to Avoid ResistanceCompletedNCT01408004Phase 2
- Association Between Hepatitis C Infection and Renal Cell CarcinomaCompletedNCT01405183
- Neo-adjuvant Temsirolimus in Patients With Advanced Renal Cell CarcinomaCompletedNCT01404104Not applicable
- Cytochrom p450 3A4 and 1A2 Phenotyping for the Individualization of Treatment With Sunitinib or Erlotinib in Cancer PatientsCompletedNCT01402089Phase 4
- Biomarkers for Angiogenesis in Renal Cell Carcinoma and Neuro-endocrine Tumours.CompletedNCT01398306
- An Observational Study of Avastin (Bevacizumab) and Interferon Alpha 2a in Patients With Metastatic Renal Cell Cancer (VERA)CompletedNCT01392729
- Safety Study of MGA271 in Refractory CancerCompletedNCT01391143Phase 1
- A Norwegian Observational Trial Evaluating the Treatment of Advanced Renal Cell Cancer Patients Under Treatment of AfinitorCompletedNCT01390519
- Dose-Escalation Study of TH-302 in Combination With Sunitinib to Treat Patients With Advanced Renal Cell Carcinoma,Gastrointestinal Stromal Tumors and Pancreatic Neuroendocrine TumorsStatus unknownNCT01381822Phase 1
- Incidence, Prevalence, and Symptom Burden Associated With Advanced Renal Cell Carcinoma in Commercially Insured Population (IHCIS)CompletedNCT01381614
- Incidence, Prevalence, and Symptom Burden Associated With Advanced Renal Cell Carcinoma in Commercially Insured Population (Pharmetrics)CompletedNCT01381601
- Cardiovascular Effects of Sunitinib Therapy (CREST)CompletedNCT01370109
- Trial of Outpatient Intravenous Interleukin-2 in Malignant Melanoma and Metastatic Kidney CancerWithdrawnNCT01355562Phase 2
- Study to Observe Safety and Efficacy of Nexavar in Treatment of Kidney CancerWithdrawnNCT01353794
- An Observational Study of Avastin (Bevacizumab) in Combination With Interferon Alpha-2a as First-Line Treatment in Patients With Advanced and/or Metastatic Renal Cell CarcinomaCompletedNCT01351571
- Sorafenib in Elderly Patients With Metastatic Renal Cell CarcinomaTerminatedNCT01342627Phase 2